PPD squeezes out a revenue growth despite COVID-19 disruption

Contract Research Organization PPD has seen its revenue nudge up in the second quarter as it navigates trial disruption while helping run one of the world’s most closely watched vaccine trials.

Revenue from the CRO crept up by 1.4% to $1.01 billion compared to Q2 2019, no small feat when so much of the CRO industry’s business has been hit by COVID chaos, and also saw net authorizations of $1.05 billion, representing 12.4% growth over the year-ago period.